View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
January 25, 2022

Revealed: pharma leaders in precision, personalised medicine

GlobalData’s Thematic Research ecosystem ranks companies on a scale of 1 to 5 based on their likelihood to tackle issues like precision and personalised medicine.

By Data Journalism Team

Novartis and Pfizer are among the companies best positioned to take advantage of future precision and personalised medicine disruption in the pharmaceuticals industry, our analysis shows.

The assessment comes from GlobalData’s Thematic Research ecosystem, which ranks companies on a scale of 1 to 5 based on their likelihood to tackle challenges like precision and personalised medicine and emerge as long-term winners of the pharmaceuticals sector.

According to our analysis, Novartis, Pfizer, Catalent, Johnson & Johnson, Roche, AstraZeneca, Sanofi, Bristol Myers Squibb, Amgen, Gilead Sciences, Patheon, Lonza, Takeda Pharmaceutical, Merck, Eli Lilly, IQVIA, AbbVie and Parexel are the companies best positioned to benefit from investments in precision and personalised medicine, all of them recording scores of 5 out of 5 in GlobalData’s Drug Development Thematic Scorecard.

The final column in the table represents the overall score given to that company when it comes to their current precision and personalised medicine position relative to their peers. A score of five indicates that a company is a dominant player in this space, while companies that score less than three are vulnerable to being left behind.

This article is based on GlobalData research figures as of 21 January 2022. For more up-to-date figures, check the GlobalData website.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology